ADC Therapeutics SA — Director's Dealing 2024

Jan 3, 2024

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ADC Therapeutics SA (ADCT)
CIK: 0001771910
Period of Report: 2024-01-02

Reporting Person: Zaki Mohamed (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	270000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$3.59	2033-01-03	Common Shares (700000)		Direct

Footnotes

F1: Represents Common Shares to be delivered in settlement of a restricted share unit award which vests 50% on the one-year anniversary of the grant date, which grant date is December 6, 2023 and on the two-year anniversary of the grant date, upon continued service through the designated vesting event.

F2: This option vests over four years from January 3, 2023, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.